10-Q quarterly report · filed Oct 29, 2026

Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 10-Q Quarterly Report

Short answer

Vanda Pharmaceuticals Inc. (VNDA) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $70M (up 24.1% year over year) with net income of −$23M.

Q3 2026 key financials · XBRL

Revenue
$70M
+24.1% YoY · +38.2% QoQ
Net income
−$23M
+0.1% YoY · +63.9% QoQ
Operating margin
-33.7%
EPS (diluted)
−$0.37
+5.1% YoY · +64.4% QoQ

Source: XBRL data from the Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 10-Q on SEC EDGAR. USD.

Vanda Pharmaceuticals Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $69.8M, up 24% YoY from $56.3M
  • Fanapt best performer, sales $38.8M, up 24% YoY; NEREUS $1.6M launch revenue
  • Gross margin 94.0% vs 94.7% YoY, based on revenue and cost of goods sold
  • Cash, equivalents and securities $140.5M vs $263.8M; operating cash outflow nine months $109.7M
  • Outlook: BYSANTI launch expected Q4 2026; HETLIOZ sales may decline significantly amid generic competition

Risk Factors

  • No material risk-factor changes from the December 31, 2025 Form 10-K
  • Carried-forward business risk: factors could materially adversely affect operations, financial condition, and common-stock price
  • Filing identifies no newly triggered regulatory, legal, operational, competitive, market, or financial risk changes

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Vanda Pharmaceuticals Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.